David A Tess Selected Research

ketohexokinase

7/2022	Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, A First-in-class Ketohexokinase Inhibitor for Metabolic Disorders and Non-alcoholic Fatty Liver Disease.
1/2022	Effect of a Ketohexokinase Inhibitor (PF-06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David A Tess Research Topics

Disease

2	Obesity 07/2022 - 09/2007
2	Non-alcoholic Fatty Liver Disease 07/2022 - 10/2020
1	Type 2 Diabetes Mellitus (MODY) 07/2022
1	Alcoholic Fatty Liver 07/2022
1	Fatty Liver 01/2022
1	Crystalluria 01/2020
1	Hypertrophy 01/2017
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2017
1	Proteinuria 01/2017
1	Fibrosis (Cirrhosis) 01/2017

Drug/Important Bio-Agent (IBA)

2	ketohexokinaseIBA 07/2022 - 01/2022
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2020
1	FructoseIBA 07/2022
1	EnzymesIBA 07/2022
1	Peptides (Polypeptides)IBA 01/2022
1	AnionsIBA 01/2022
1	Acetyl-CoA CarboxylaseIBA 10/2020
1	Protein Isoforms (Isoforms)IBA 01/2017
1	Blood Glucose (Blood Sugar)IBA 01/2017
1	Biomarkers (Surrogate Marker)IBA 01/2017
1	Ramipril (Altace)FDA LinkGeneric 01/2017
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2017

Therapy/Procedure

2	Therapeutics 01/2017 - 09/2007